Abstract
High dose inhaled salbutamol is increasingly used in the management of chronic obstructive airways disease. To determine the range of doses to achieve optimal bronchodilatation and the proportion of patients requiring high dose therapy we have studied 23 patients with chronic obstructive airways disease. Cumulative dose responses were measured to six incremental doses of salbutamol (0.2 to 1.2 mg) delivered by metered dose inhaler. Results were analysed by polynomial regression to calculate the smallest dose required to produce 90% maximal bronchodilatation in each patient. While 5/23 (22%) required greater than 1 mg the majority, 14/23 (61%), achieved 90% maximal bronchodilation with salbutamol 0.6 mg or less. The 8 patients with severe airflow limitation (FEV1 less than or equal to 1 litre) showed a similar pattern of response. We conclude that in chronic obstructive airways disease there are wide individual variations in the dose of inhaled salbutamol producing 90% maximal bronchodilatation with only a minority requiring high dose therapy.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Assoufi B. K., Hodson M. E. High dose salbutamol in chronic airflow obstruction: comparison of nebulizer with Rotacaps. Respir Med. 1989 Sep;83(5):415–420. doi: 10.1016/s0954-6111(89)80073-3. [DOI] [PubMed] [Google Scholar]
- Barnes P. J., Pride N. B. Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects. Br J Clin Pharmacol. 1983 Jun;15(6):677–682. doi: 10.1111/j.1365-2125.1983.tb01549.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Britton J., Tattersfield A. Comparison of cumulative and non-cumulative techniques to measure dose-response curves for beta agonists in patients with asthma. Thorax. 1984 Aug;39(8):597–599. doi: 10.1136/thx.39.8.597. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cochrane G. M., Prior J. G., Rees P. J. Home nebulisers for airflow limitation. Br Med J (Clin Res Ed) 1985 Jun 1;290(6482):1608–1609. doi: 10.1136/bmj.290.6482.1608. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Connellan S. J., Gough S. E. The effects of nebulized salbutamol on lung function and exercise tolerance in patients with severe airflow obstruction. Br J Dis Chest. 1982 Apr;76(2):135–142. [PubMed] [Google Scholar]
- Jenkins S. C., Moxham J. High dose salbutamol in chronic bronchitis: comparison of 400 micrograms, 1 mg, 1.6 mg, 2 mg and placebo delivered by Rotahaler. Br J Dis Chest. 1987 Jul;81(3):242–247. doi: 10.1016/0007-0971(87)90156-2. [DOI] [PubMed] [Google Scholar]
- Lipworth B. J., Clark R. A., Dhillon D. P., Brown R. A., McDevitt D. G. Beta-adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma. Br J Clin Pharmacol. 1988 Nov;26(5):527–533. doi: 10.1111/j.1365-2125.1988.tb05292.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- O'Driscoll B. R., Kay E. A., Taylor R. J., Bernstein A. Home nebulizers: can optimal therapy be predicted by laboratory studies? Respir Med. 1990 Nov;84(6):471–477. doi: 10.1016/s0954-6111(08)80111-4. [DOI] [PubMed] [Google Scholar]
- Prior J. G., Cochrane G. M. Assessment of optimum dose of inhaled terbutaline in patients with chronic asthma: the use of simple, cumulative dose-response curves. Br J Dis Chest. 1982 Jul;76(3):266–268. [PubMed] [Google Scholar]
- The nebuliser epidemic. Lancet. 1984 Oct 6;2(8406):789–790. [PubMed] [Google Scholar]
- Vathenen A. S., Britton J. R., Ebden P., Cookson J. B., Wharrad H. J., Tattersfield A. E. High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis. 1988 Oct;138(4):850–855. doi: 10.1164/ajrccm/138.4.850. [DOI] [PubMed] [Google Scholar]